NAC +taVNS in IDM Who Are Poor Oral Feeders
Primary Purpose
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation
Status
Active
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
N acetyl cysteine + vagus nerve stimulation
Sponsored by
About this trial
This is an interventional treatment trial for Infant of Diabetic Mother
Eligibility Criteria
Inclusion Criteria:
- Infants of diabetic mothers who are failing oral feeding, >39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates
Exclusion Criteria:
- Unstable infants or those requiring positive pressure respiratory support
- Infants <39 weeks gestation at enrollment
- Major unrepaired congenital anomalies or anomalies that limit feeding volumes
- Infants with cardiomyopathy
- Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving
Sites / Locations
- Medical University of South Carolina
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
NAC + taVNS
Arm Description
NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
Outcomes
Primary Outcome Measures
Daily oral feeding volumes
ml/kg/d of oral feeds, slope of change of oral feeding volumes before and after NAC + taVNS
Secondary Outcome Measures
Metabolite concentrations in basal ganglia
[GSH] and other CNS metabolites by MRS before, and after 3-4 days of NAC and after NAC+taVNS treatment
Full Information
NCT ID
NCT04632069
First Posted
November 12, 2020
Last Updated
March 15, 2023
Sponsor
Medical University of South Carolina
Collaborators
National Institute of General Medical Sciences (NIGMS)
1. Study Identification
Unique Protocol Identification Number
NCT04632069
Brief Title
NAC +taVNS in IDM Who Are Poor Oral Feeders
Official Title
N-acetylcysteine Plus Transcutaneous Vagus Nerve Stimulation in Infants of Diabetic Mothers Who Fail Oral Feeding
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 12, 2021 (Actual)
Primary Completion Date
January 10, 2023 (Actual)
Study Completion Date
October 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of South Carolina
Collaborators
National Institute of General Medical Sciences (NIGMS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Infants of diabetic mothers who are failing to learn oral feeding by term age equivalence have greater CNS oxidative stress, which interact to predict poor neuroplasticity response to transcutaneous vagus nerve stimulation paired with oral feeding. We propose treating the oxidative stress in IDM infants prior to initiating taVNS, with an FDA-approved antioxidant (N-acetylcysteine, NAC) to improve CNS oxidative stress, which in turn regulates expression of many genes including BDNF, that may enhance motor learning.
Detailed Description
Our group has recently conducted a first-in-infants pilot trial of pairing transcutaneous auricular vagus nerve stimulation (taVNS) with feeding to assist learning oromotor skills. We are enrolling preterm and HIE infants who are failing to learn oral feeds and clinically determined to need a G-tube. In preliminary data, taVNS paired with one or two daily feedings for 2 weeks resulted in 50% of infants attaining full feeds and avoiding G-tube.
A notable number of non-responders were infants of diabetic mothers (IDM) exposed to poor glucose control during pregnancy, all of whom required a G-tube. Uncontrolled maternal hyperglycemia is associated with increased systemic and neuro-inflammation, CNS oxidative stress, DNA damage, and worse neonatal outcomes compared to infants of euglycemic mothers. In neonatal animal models, hyperglycemia has been shown to decrease BDNF, alter long-term synaptogenesis and hippocampal neurochemistry, with ongoing CNS oxidative stress and inhibition of the cortical neuronal plasticity required for learning. In our pilot trial of taVNS-paired feeding, CNS glutathione concentrations (GSH), a MR spectroscopy (MRS) marker of oxidative stress, had significant interaction with IDM in predicting outcome, strongly suggesting that ongoing CNS oxidative stress contributes to neuropathology in IDMs failing oral feeding.
NAC is an FDA-approved antioxidant that is safe and crosses the blood brain barrier, increasing CNS GSH. NAC reduces CNS oxidative stress, enhances learning and provides a neuroprotective effect after brain injury in our and others neonatal HI and neuroinflammatory animal models. Both GSH and BDNF enhance neuroplasticity. Therefore, we hypothesize that pre-treatment with NAC in IDMs who are failing oral feeding, followed by taVNS-paired feeding, will decrease oxidative stress induced by maternal hyperglycemia and IDM-associated brain injury, and increase response to taVNS-paired feeding rehabilitation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.
Masking
None (Open Label)
Masking Description
Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NAC + taVNS
Arm Type
Experimental
Arm Description
NAC will be given via nasogastric tube (n,g.) 100mg/kg loading dose, then 75mg/kg/dose n.g. q 6h, administered 1h before a feed, for a total of 14 days. taVNS will be administered to left ear during active sucking with 2 daily feedings starting after 4 days of NAC, continuing for 10 days.
Intervention Type
Combination Product
Intervention Name(s)
N acetyl cysteine + vagus nerve stimulation
Other Intervention Name(s)
NAC, Acetadote, taVNS
Intervention Description
NAC x 14 days, taVNS x 10 days
Primary Outcome Measure Information:
Title
Daily oral feeding volumes
Description
ml/kg/d of oral feeds, slope of change of oral feeding volumes before and after NAC + taVNS
Time Frame
20 days
Secondary Outcome Measure Information:
Title
Metabolite concentrations in basal ganglia
Description
[GSH] and other CNS metabolites by MRS before, and after 3-4 days of NAC and after NAC+taVNS treatment
Time Frame
14 days
Other Pre-specified Outcome Measures:
Title
Diffusion Kurtosis Imaging (DKI)
Description
DKI metrics in white matter tracts before and after NAC+taVNS treatment
Time Frame
14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Weeks
Maximum Age & Unit of Time
5 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infants of diabetic mothers who are failing oral feeding, >39weeks gestation at enrollment, who are clinically stable, on minimal respiratory support (nasal cannula or room air), and clinical team has determined are G-tube candidates
Exclusion Criteria:
Unstable infants or those requiring positive pressure respiratory support
Infants <39 weeks gestation at enrollment
Major unrepaired congenital anomalies or anomalies that limit feeding volumes
Infants with cardiomyopathy
Repeated episodes of autonomic instability (apnea/ bradycardia) not self resolving
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dorothea Jenkins, MD
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
will share de-identified data after publication of results
IPD Sharing Time Frame
after publication of results
IPD Sharing Access Criteria
written request of PI
Citations:
PubMed Identifier
32256328
Citation
Badran BW, Jenkins DD, Cook D, Thompson S, Dancy M, DeVries WH, Mappin G, Summers P, Bikson M, George MS. Transcutaneous Auricular Vagus Nerve Stimulation-Paired Rehabilitation for Oromotor Feeding Problems in Newborns: An Open-Label Pilot Study. Front Hum Neurosci. 2020 Mar 18;14:77. doi: 10.3389/fnhum.2020.00077. eCollection 2020.
Results Reference
background
PubMed Identifier
30146041
Citation
Badran BW, Jenkins DD, DeVries WH, Dancy M, Summers PM, Mappin GM, Bernstein H, Bikson M, Coker-Bolt P, George MS. Transcutaneous auricular vagus nerve stimulation (taVNS) for improving oromotor function in newborns. Brain Stimul. 2018 Sep-Oct;11(5):1198-1200. doi: 10.1016/j.brs.2018.06.009. Epub 2018 Jun 30. No abstract available.
Results Reference
background
Learn more about this trial
NAC +taVNS in IDM Who Are Poor Oral Feeders
We'll reach out to this number within 24 hrs